OBI Pharma (TWO:4174) — Stock Price
OBI Pharma (TWO:4174) is currently trading at NT$26.30 TWD, up 1.35% today. Over the past 52 weeks, shares have ranged between NT$23.25 and NT$50.50. This page tracks OBI Pharma's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 4174 market cap.
OBI Pharma (4174) Stock Price Chart — Daily History & Trading Volume
The chart below tracks OBI Pharma's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
OBI Pharma Income Statement — Revenue, Profit & Earnings by Year
OBI Pharma's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$58.58 Million | NT$62.68 Million | NT$41.55 Million | NT$4.71 Million | NT$18.77 Million |
| Cost of Revenue | NT$136.10 Million | NT$138.95 Million | NT$115.05 Million | NT$44.85 Million | NT$44.36 Million |
| Gross Profit | NT$-77.53 Million | NT$-76.27 Million | NT$-73.50 Million | NT$-40.14 Million | NT$-25.59 Million |
| Research & Development | NT$1.73 Billion | NT$1.97 Billion | NT$1.70 Billion | NT$1.77 Billion | NT$1.45 Billion |
| SG&A | NT$361.96 Million | NT$326.78 Million | NT$319.28 Million | NT$309.76 Million | NT$240.83 Million |
| Total Operating Expenses | NT$2.23 Billion | NT$2.43 Billion | NT$2.02 Billion | NT$2.08 Billion | NT$1.69 Billion |
| Operating Income | NT$-2.17 Billion | NT$-2.37 Billion | NT$-2.09 Billion | NT$-1.91 Billion | NT$-1.74 Billion |
| EBITDA | — | — | NT$-1.02 Billion | NT$-1.67 Billion | NT$-1.52 Billion |
| EBIT | — | — | NT$-1.27 Billion | NT$-1.91 Billion | NT$-1.74 Billion |
| Interest Expense | NT$13.13 Million | NT$10.65 Million | NT$7.94 Million | NT$3.99 Million | NT$3.80 Million |
| Income Before Tax | NT$-2.26 Billion | NT$-2.50 Billion | NT$-1.28 Billion | NT$-1.92 Billion | NT$-1.74 Billion |
| Income Tax Expense | — | — | NT$-9.59 Million | NT$-17.77 Million | NT$-24.36 Million |
| Net Income | NT$-2.05 Billion | NT$-2.31 Billion | NT$-1.27 Billion | NT$-1.90 Billion | NT$-1.72 Billion |
OBI Pharma Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes OBI Pharma's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$3.42 Billion | NT$5.65 Billion | NT$5.60 Billion | NT$6.63 Billion | NT$4.49 Billion |
| Total Current Assets | NT$1.58 Billion | NT$3.44 Billion | NT$3.16 Billion | NT$5.03 Billion | NT$2.85 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$427.00 Million | NT$1.40 Billion | NT$1.88 Billion | NT$31.46 Million | NT$141.77 Million |
| Net Receivables | NT$10.30 Million | NT$4.20 Million | NT$30.07 Million | NT$28.27 Million | NT$23.27 Million |
| Inventory | NT$18.43 Million | NT$27.73 Million | NT$25.93 Million | NT$21.97 Million | NT$9.56 Million |
| Property, Plant & Equipment | — | — | — | NT$1.18 Billion | NT$1.15 Billion |
| Goodwill | — | — | — | NT$61.15 Million | NT$61.15 Million |
| Total Liabilities | NT$696.13 Million | NT$833.38 Million | NT$650.45 Million | NT$497.57 Million | NT$615.95 Million |
| Total Current Liabilities | NT$350.56 Million | NT$412.37 Million | NT$158.62 Million | NT$221.14 Million | NT$327.22 Million |
| Long-term Debt | NT$29.46 Million | NT$48.22 Million | NT$14.00 Million | NT$21.00 Million | NT$28.00 Million |
| Net Debt | — | — | NT$-398.22 Million | NT$-4.49 Billion | NT$-2.22 Billion |
| Total Stockholder Equity | NT$1.89 Billion | NT$3.81 Billion | NT$3.81 Billion | NT$4.63 Billion | NT$2.72 Billion |
| Retained Earnings | NT$-8.62 Billion | NT$-7.88 Billion | NT$-5.57 Billion | NT$-4.52 Billion | NT$-2.91 Billion |
OBI Pharma Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how OBI Pharma generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$-2.02 Billion | NT$-1.83 Billion | NT$-1.65 Billion | NT$-1.62 Billion | NT$-1.06 Billion |
| Capital Expenditures | NT$48.27 Million | NT$119.56 Million | NT$108.16 Million | NT$300.56 Million | NT$245.18 Million |
| Free Cash Flow | NT$-2.07 Billion | NT$-1.95 Billion | NT$-1.76 Billion | NT$-1.92 Billion | NT$-1.31 Billion |
| Investing Cash Flow | — | — | — | NT$-169.89 Million | NT$82.68 Million |
| Financing Cash Flow | — | — | NT$607.07 Million | NT$4.01 Billion | NT$163.75 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | NT$31.75 Million | NT$63.98 Million | NT$119.20 Million | NT$149.00 Million | NT$54.02 Million |
| Depreciation | NT$227.16 Million | NT$222.25 Million | NT$248.95 Million | NT$246.61 Million | NT$216.28 Million |
| Change in Cash | NT$-972.72 Million | NT$832.77 Million | NT$-3.84 Billion | NT$2.23 Billion | NT$-826.12 Million |
OBI Pharma Earnings History — EPS Actual vs. Analyst Estimates
Track OBI Pharma's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 11, 2026 | — | — | — |
| Mar 09, 2026 | — | — | — |
| Nov 03, 2025 | — | — | — |
| Jul 31, 2025 | — | — | — |
| May 12, 2025 | — | — | — |
| Mar 10, 2025 | — | — | — |
| Nov 04, 2024 | — | — | — |
| Mar 13, 2023 | -2.52 | — | — |